Prophylactic Intralesional Botulinum Toxin Type A Versus Triamcinolone Acetonide Followed by Combination Therapy for Keloid Prevention and Treatment in High-Risk Orthopedic Surgery Patients: A Retrospective Comparative Study.
Ahmedov Anvar A, Karabulut Furkan F, Çiçek Ali Can AC, Aksay Mehmet Fatih MF
To compare the efficacy of prophylactic intralesional botulinum toxin type A (BTX-A) versus triamcinolone acetonide (TAC) in keloid-prone patients undergoing orthopedic surgery, and to evaluate outcomes of subsequent combination therapy for those developing postoperative keloids. Seventy-four patients with documented keloid history were grouped by prophylactic agent per surgeon's routine practice: BTX-A (n = 39) and TAC (n = 35). Patients developing keloids received combined BTX-A+TAC monthly for three sessions. Outcomes included formation rates, time to formation, lesional dimensions, percentage improvements, Stony Brook Scar Evaluation Scale (SBSES) scores, complications, and recurrence. Formation rates were similar (82.1% vs. 85.7%, p = 0.670). BTX-A prophylaxis was associated with longer time to formation (8.03 ± 2.18 vs. 4.87 ± 2.76 months, p < 0.001), smaller transverse diameter (0.96 ± 1.12 vs. 1.81 ± 1.47 mm, p < 0.001), and a trend toward smaller volume (215.23 ± 613.01 vs. 570.19 ± 1542.46 mm3, p = 0.049). After combination therapy, TAC-prophylaxed patients had superior thickness (87.87 ± 4.70% vs. 79.50 ± 11.70%, p = 0.006) and volume improvement (91.00 ± 4.22% vs. 82.72 ± 11.56%, p = 0.008), and higher post-treatment SBSES scores (4.50 ± 0.68 vs. 4.00 ± 0.80, p = 0.012). All patients improved significantly (p < 0.001). Complication rates were similar (p = 0.530), with skin atrophy most frequent (46.7%). BTX-A prophylaxis was associated with longer time to keloid formation and a trend toward smaller volume, while TAC-prophylaxed patients showed enhanced response to subsequent combination therapy. Combined BTX-A+TAC appears well tolerated and potentially effective for managing keloids in high-risk surgical patients. This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .